Shares of Neos Therapeutics Inc. (NASDAQ:NEOS) traded down 3.4% during mid-day trading on Tuesday . The stock traded as low as $7.11 and last traded at $7.13, with a volume of 66,015 shares traded. The stock had previously closed at $7.38.

Several analysts recently issued reports on the company. Royal Bank Of Canada cut their target price on Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating for the company in a research report on Tuesday, May 17th. Zacks Investment Research cut Neos Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 18th. BMO Capital Markets reiterated a “buy” rating and set a $15.00 target price on shares of Neos Therapeutics in a research report on Tuesday, July 19th. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Neos Therapeutics in a research report on Wednesday, May 18th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $21.75.

The stock’s market capitalization is $114.90 million. The firm’s 50-day moving average is $8.76 and its 200-day moving average is $9.56.

Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.16) by $0.49. The company earned $1.49 million during the quarter, compared to the consensus estimate of $1.48 million. On average, equities analysts expect that Neos Therapeutics Inc. will post ($5.38) earnings per share for the current fiscal year.

In other news, Director Alan L. Heller purchased 10,000 shares of the firm’s stock in a transaction on Thursday, May 19th. The shares were bought at an average cost of $7.61 per share, for a total transaction of $76,100.00. Following the completion of the purchase, the director now directly owns 379,888 shares of the company’s stock, valued at $2,890,947.68. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gregory J. Robitaille purchased 7,442 shares of the firm’s stock in a transaction on Wednesday, May 18th. The shares were purchased at an average price of $7.55 per share, for a total transaction of $56,187.10. Following the completion of the purchase, the director now directly owns 55,677 shares of the company’s stock, valued at $420,361.35. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Neos Therapeutics stock. Marshall Wace LLP boosted its position in Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned approximately 0.60% of Neos Therapeutics worth $1,377,000 at the end of the most recent reporting period.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.